It’s part of a larger battle between Louisiana officials and big health care companies over prescription drug prices.

CVS Health Corporation is rated a Buy with a strong turnaround driving industry-leading results. Learn more about CVS stock ...

CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady ...

A Florida judge on Monday declared a mistrial in a lawsuit that accused Walmart, CVS and Walgreens of flooding the state with ...

CVS Health Corp. raised its full-year profit forecast and said earnings would rise in 2026, a sign of hope as it navigates a ...

The healthcare giant expects its turnaround efforts to pay off as it raised its full-year outlook and expects that momentum ...

CVS Caremark settles pharmacy underpayment allegations for $5M, reimbursing Oklahoma pharmacies for 68,099 prescriptions filled from 2024 to 2025.

CVS is a strong buy now, with rising earnings, solid dividends, and steady growth prospects despite industry challenges. Read ...

Looking back at some of the themes that defined dealmaking in 2025. This special edition of the Wire highlights PE Hub’s most ...

CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.

In addition to the updates for 2025, CVS offered its first look at expected earnings for 2026. The company said it ...